Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SUTRO BIOPHARMA, INC. Director's Dealing 2021

Aug 11, 2021

34319_dirs_2021-08-11_92c79937-43ce-4d46-a4df-22f7017c53cf.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SUTRO BIOPHARMA, INC. (STRO)
CIK: 0001382101
Period of Report: 2021-08-09

Reporting Person: Chung Jane (Chief Commercial Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-08-09 Stock Option (right to buy) $18.37 A 160000 Acquired 2031-08-08 Common Stock (160000) Direct
2021-08-09 Restricted Stock Unit (RSU) $ A 75000 Acquired 2025-08-09 Common Stock (75000) Direct

Footnotes

F1: The option vests as to 1/4th of the total shares on August 9, 2022 and then 1/48th of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on August 9, 2025, subject to the reporting person's provision of service to the issuer on each vesting date.

F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.

F3: The RSUs vest as to 1/4th of the total shares annually beginning on August 9, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.